Protagonist Therapeutics Inc

2026. okt. 16. 20:02 UTC

Protagonist Therapeutics Inc shares are sharply lower, diverging from a recent trend of higher daily closes, with unusually high market volume today.

2026. okt. 15. 19:46 UTC

UBS has initiated a Buy rating on Protagonist Therapeutics Inc with a price target of $184, highlighting the commercial potential of PN-881.

2026. okt. 14. 20:07 UTC

PTGX declines after Leerink initiates coverage with outperform rating.

2026. okt. 13. 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, diverging from recent upward momentum, with unusually high trading volume observed today.

2026. okt. 12. 20:06 UTC

Protagonist Therapeutics receives a Buy rating from UBS with a $184 price target, while Leerink Partners sets an Outperform rating with a $190 target.

2026. okt. 9. 22:21 UTC

Protagonist Therapeutics Inc shares traded modestly lower during after-market hours on Friday after peaking shortly after the regular session ended.

2026. okt. 8. 20:07 UTC

Protagonist Therapeutics Inc shares fell amid a broadly lower market, trading near the lower end of its one-month range and below its 20-day moving average.

2026. okt. 7. 20:01 UTC

Protagonist Therapeutics Inc is trading higher, influenced by gains in the Biotechnology sector, despite pulling back from earlier session highs and high market volume.

2026. okt. 6. 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining near the lower end of their one-month range and below the 20-day moving average.

2026. okt. 1. 20:07 UTC

Protagonist Therapeutics Inc shares fell as the broader market continued its decline, marking four consecutive days of lower closes and remaining below the 20-day moving average.

2026. szept. 30. 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply after peaking earlier in the day, finishing below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 29. 19:15 UTC

Protagonist Therapeutics Inc shares fell, now near the low end of their one-month range, despite a user reporting a price target in the low $130s.

2026. szept. 25. 19:51 UTC

Protagonist Therapeutics Inc shares are advancing significantly, showing strong upward momentum with notable trading activity since Thursday's close.

2026. szept. 24. 19:46 UTC

Protagonist Therapeutics Inc shares fell sharply, reaching a low before noon and trading significantly below its 20-day moving average amid ongoing biotechnology sector weakness.

2026. szept. 23. 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, continuing a decline since Tuesday, with trading volume unusually high and prices near the lower end of their one-month range.

2026. szept. 18. 20:06 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

2026. szept. 17. 19:46 UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

2026. szept. 16. 19:13 UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

2026. szept. 15. 20:07 UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

2026. szept. 11. 20:08 UTC

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

2026. szept. 9. 20:07 UTC

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2026. szept. 2. 20:08 UTC

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

2026. szept. 1. 19:36 UTC

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

2026. aug. 28. 20:02 UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

2026. aug. 27. 20:07 UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

2026. aug. 26. 20:08 UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

2026. aug. 25. 23:36 UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

2026. aug. 24. 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

2026. aug. 21. 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

2026. aug. 20. 19:31 UTC

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.